Rational targeting of resistance pathways to resensitize drug-resistant mutants. (A) Clonogenic survival assay of MAP2K1 mutant CCK-81 cells when treated with Cetuximab, Trametinib, or a combination of the two drugs. Heat maps of normalized viability effects per well are shown below each cell line. (B) Immunoblot of the effect of combing Cetuximab and Trametinib (MEK inhibitor) on MAPK signaling in MAP2K1 mutant CCK-81 cells. Cells were treated with Cetuximab (10 µg/mL), Trametinib (5 nM), or both for 6 h. MET was also overexpressed as a positive control.